The CardiAMP Heart Failure trial: A randomized controlled pivotal trial of high-dose autologous bone marrow mononuclear cells using the CardiAMP cell therapy system in patients with post-myocardial infarction heart failure: Trial rationale and study design.
Am Heart J
; 201: 141-148, 2018 07.
Article
en En
| MEDLINE
| ID: mdl-29803986
ABSTRACT
BACKGROUND:
Heart failure following myocardial infarction is a common, disabling, and deadly condition. Direct injection of autologous bone marrow mononuclear cells into the myocardium may result in improved functional recovery, relieve symptoms, and improve other cardiovascular outcomes.METHODS:
CardiAMP-HF is a randomized, double-blind, sham-controlled, pivotal trial designed to investigate the safety and efficacy of autologous bone marrow mononuclear cells treatment for patients with medically refractory and symptomatic ischemic cardiomyopathy. The primary end point is change in 6-minute walk distance adjusted for major adverse cardiovascular events at 12 months following treatment. Particularly novel aspects of this trial include a cell potency assay to screen subjects who have bone marrow cell characteristics that suggest a favorable response to treatment, a point-of-care treatment method, a high target dose of 200 million cells, and an efficient transcatheter intramyocardial delivery method that is associated with high cell retention.CONCLUSIONS:
This novel approach may lead to a new treatment for those with ischemic heart disease suffering from medically refractory heart failure.
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Volumen Sistólico
/
Monocitos
/
Función Ventricular Izquierda
/
Trasplante de Médula Ósea
/
Insuficiencia Cardíaca
/
Infarto del Miocardio
Tipo de estudio:
Clinical_trials
/
Etiology_studies
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Límite:
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Revista:
Am Heart J
Año:
2018
Tipo del documento:
Article